JBM (Healthcare) Limited provided earnings guidance for the year ended 31 March 2023. For the year, the Group is expected to record an increase by not less than 130% in the consolidated profit attributable to Shareholders for the year ended 31 March 2023 ("Consolidated Profit") as compared to that for the year ended 31 March 2022. The significant increase in Consolidated Profit was primarily attributable to the progressive
enhancement of retail spending sentiment, boosted by the phased relaxation of the pandemic restrictive measures throughout the fiscal year in the Hong Kong Special Administrative Region ("Hong Kong"). This development fostered a gradual recovery in the Group's overall sales, leading to a noteworthy revenue surge, coupled with the strong sales growth of its cross-border e-commerce platforms.